LENZ Therapeutics, Inc./$LENZ
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About LENZ Therapeutics, Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Ticker
$LENZ
Sector
Primary listing
Employees
-
Headquarters
Website
LENZ Metrics
BasicAdvanced
$615M
-
-$2.11
-
-
Price and volume
Market cap
$615M
52-week high
$50.40
52-week low
$16.54
Average daily volume
1.2M
Financial strength
Total debt to equity
0.509
Profitability
EBITDA (TTM)
-67.818
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-336.47%
Operating margin (TTM)
-388.00%
Effective tax rate (TTM)
-0.86%
Management effectiveness
Valuation
Price to revenue (TTM)
36.636
Price to book
3.17
Price to tangible book (TTM)
3.17
Growth
Earnings per share change (TTM)
-21.56%
Bulls say / Bears say
LENZ’s VIZZ (aceclidine ophthalmic solution) 1.44% was approved by the FDA on July 31, 2025, making it the first aceclidine-based eye drop for presbyopia and giving LENZ a first-mover advantage in the 128 million-patient US market (PharmExec).
In three randomized, double-masked Phase 3 CLARITY trials, VIZZ met all primary and secondary endpoints for near vision improvement, with results seen in 30 minutes and effects lasting up to 10 hours. This duration distinguishes it from current treatments (PharmExec).
LENZ began nationwide distribution of samples to eye care professionals in October 2025, with plans for broad consumer availability by mid-Q4 2025, demonstrating solid pre-launch commercial plans and readiness (American Pharmaceutical Review).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LENZ Therapeutics, Inc. stock?
LENZ Therapeutics, Inc. (LENZ) has a market cap of $615M as of November 07, 2025.
What is the P/E ratio for LENZ Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for LENZ Therapeutics, Inc. (LENZ) stock is 0 as of November 07, 2025.
Does LENZ Therapeutics, Inc. stock pay dividends?
No, LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next LENZ Therapeutics, Inc. dividend payment date?
LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders.
What is the beta indicator for LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. (LENZ) does not currently have a Beta indicator.